Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 1/20 | 0.47 |
| ▸ | MMP12 | P39900 | 1/20 | 0.47 |
| ▸ | MELK | Q14680 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | GABRP | O00591 | 1/20 | 0.40 |
| ▸ | GABRD | O14764 | 1/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.40 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.40 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.40 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.40 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.40 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.40 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.40 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.40 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.40 |
| ▸ | GABRE | P78334 | 1/20 | 0.40 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.40 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.40 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.40 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11557111 | 0.94 | MMP2 (0.43) | MMP2MMP12MELKHRH3GABRP | |
| SCHEMBL11548458 | 0.88 | HRH3 (0.44) | MMP2MMP12MELKHRH3GABRP | |
| SCHEMBL6446069 | 0.87 | MMP2 (0.55) | MMP2MMP12MELKHRH3GABRP | |
| SCHEMBL12139282 | 0.82 | GABRP (0.43) | MMP2MMP12HRH3GABRPGABRD | |
| SCHEMBL9672111 | 0.80 | MMP2 (0.50) | MMP2MMP12MELKHRH3GABRP | |
| SCHEMBL16685905 | 0.79 | GABRP (0.47) | MMP2MMP12HRH3GABRPGABRD | |
| SCHEMBL508102 | 0.78 | PYCR1 (0.41) | PYCR1CYP2A6ALDH1A1ACACBLMNA | |
| SCHEMBL11214760 | 0.78 | APP (0.50) | MMP2MMP12MELKHRH3GABRP | |
| SCHEMBL17971132 | 0.77 | PYCR1 (0.38) | PYCR1CYP2A6ACACBLMNAKDM4E | |
| SCHEMBL11555881 | 0.77 | GABRP (0.40) | HRH3GABRPGABRDGABRA1GABRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117466790-B | Preparation method of alpha-sulfinylated carbonyl compound | 西北师范大学 | 2024-05-28 | — | — | CN | disclosed |
| CN-117466790-A | Preparation method of alpha-sulfinylated carbonyl compound | 西北师范大学 | 2024-01-30 | — | — | CN | disclosed |
| US-11787813-B2 | Substituted pyrazolopyrimidines and substituted purines and their use as ubiquitin-specific-processing protease 1 (USP1) inhibitors | KSQ Therapeutics, Inc. (US) | 2023-10-17 | — | — | US | disclosed |
| US-11697646-B2 | Triazole N-linked carbamoyl cyclohexyl acids as LPA antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-07-11 | — | — | US | disclosed |
| US-20230203046-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES AND SUBSTITUTED PURINES AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS | KSQ Therapeutics, Inc. | 2023-06-29 | — | — | US | disclosed |
| CN-110467514-B | Preparation method of alpha-halogenated unsaturated aldehyde ketone | 上海应用技术大学 | 2023-03-28 | — | — | CN | disclosed |
| CN-110483430-B | Preparation method of isoxazole derivative | 上海应用技术大学 | 2023-02-10 | — | — | CN | disclosed |
| CN-114014886-B | Silicon fused ring naphthopyran photochromic compound and preparation method and application thereof | 南开大学 | 2022-12-27 | — | — | CN | disclosed |
| CN-110483429-B | Preparation method of 3, 5-disubstituted-4, 5-dihydroisoxazole | 上海应用技术大学 | 2022-10-14 | — | — | CN | disclosed |
| US-20220127215-A1 | A COPPER-CATALYZED METHOD AND APPLICATION FOR PREPARING ALDEHYDES OR KETONES BY OXIDIZING ALCOHOLS WITH OXYGEN AS AN OXIDANT | FUDAN UNIVERSITY (CN) | 2022-04-28 | — | — | US | disclosed |
| EP-1032584-A1 | NOVEL 19-NOR STEROIDS SUBSTITUTED IN POSITION 11BETA, PREPARATION METHOD AND INTERMEDIATES, APPLICATION AS MEDICINES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | HOECHST MARION ROUSSEL (FR) | 2000-09-06 | — | — | EP | disclosed |
| EP-1020445-A1 | FUSED PYRIDINE DERIVATIVES | Eisai Co., Ltd. (JP) | 2000-07-19 | — | — | EP | disclosed |
| WO-1999025725-A1 | NOVEL 19-NOR STEROIDS SUBSTITUTED IN POSITION 11β, PREPARATION METHOD AND INTERMEDIATES, APPLICATION AS MEDICINES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | HOECHST MARION ROUSSEL (FR) | 1999-05-27 | — | — | WO | disclosed |
| US-5561143-A | ANTICHOLESTEROL AGENTS, ANTILIPEMIC AGENTS | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1996-10-01 | — | — | US | disclosed |
| US-5534532-A | ANTICHOLESTEROL AGENTS, SQUALENE SYNTHASE INHIBITOR | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1996-07-09 | — | — | US | disclosed |
| US-5455260-A | Anticholesterol agents; reduction of serum cholesterol without reducing mevalonic metabolite synthesis; side effect | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1995-10-03 | — | — | US | disclosed |
| WO-1994027601-A1 | ALIPHATIC AMINO BIS-ARYL SQUALENE SYNTHASE INHIBITORS | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1994-12-08 | — | — | WO | disclosed |
| EP-0294228-B1 | NOVEL HETEROCYCLIC PESTICIDAL COMPOUNDS | THE WELLCOME FOUNDATION LIMITED (GB) | 1992-08-26 | — | — | EP | disclosed |
| EP-0294228-A2 | Novel heterocyclic pesticidal compounds | THE WELLCOME FOUNDATION LIMITED (GB) | 1988-12-07 | — | — | EP | disclosed |
| US-4322432-A | Cyclopropanecarboxylic acid alkynyl esters, processes for producing them, and their use as pesticides | CIBA-GEIGY CORPORATION (US) | 1982-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11787813-B2 | Substituted pyrazolopyrimidines and substituted purines and their use as ubiquitin-specific-processing protease 1 (USP1) inhibitors | USP1, UPP1, USP2 | MMP2 2193/4885MMP12 2582/4885MELK 2945/4885 |
| US-20220127215-A1 | A COPPER-CATALYZED METHOD AND APPLICATION FOR PREPARING ALDEHYDES OR KETONES BY OXIDIZING ALCOHOLS WITH OXYGEN AS AN OXIDANT | SOD1, ALDH2, AOC2 | MMP2 2302/4885MMP12 1800/4885MELK 2079/4885 |
| US-20230203046-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES AND SUBSTITUTED PURINES AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS | USP1, UPP1, USP2 | MMP2 2193/4885MMP12 2582/4885MELK 2945/4885 |
| US-11697646-B2 | Triazole N-linked carbamoyl cyclohexyl acids as LPA antagonists | LPAR3, LPAR1, LPAR2 | MMP2 2545/4885MMP12 3234/4885MELK 2837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.